Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01321463 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 377
- Enrollment target
NCT01321463: Completed Phase 2 study, sponsored by Pfizer.
NCT01321463 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 377 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (183% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01321463, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 377 participants
- Enrollment target
Study Summary
PH-797804 is an oral ant-inflammatory drug that may reduce the inflammation that is associated with COPD. PH-797804 will be dosed to patients with COPD to evaluate its potential safety and efficacy profile in COPD.
Interventions
- DRUG Placebo
- DRUG PH-797804
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT01321463 record still lists
NCT01321463 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (183% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01321463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01321463 about?
NCT01321463 is a clinical study titled "Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination". PH-797804 is an oral ant-inflammatory drug that may reduce the inflammation that is associated with COPD. PH-797804 will be dosed to patients with COPD to evaluate its potential safety and efficacy profile in COPD.
What is the current status of trial NCT01321463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 377 participants. The study started on 2011-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01321463?
The interventions under investigation include: Placebo (DRUG), PH-797804 (DRUG).
Who is sponsoring clinical trial NCT01321463?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01321463's enrollment target sits among peer trials
377 115th of 2000 higher than 1,885 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia